pentoxifylline PKB171 gel

Pentoxifylline PKB171 gel is a **topically administered vaginal gel formulation** containing pentoxifylline as the active ingredient, under investigation for the treatment of **asthenozoospermia-associated infertility** in couples. Pentoxifylline is a **phosphodiesterase inhibitor** known to improve sperm motility in vitro by increasing intracellular cyclic AMP levels, thus potentially improving the chances of conception in couples where male partners have reduced sperm motility. PKB171 gel is not yet approved by regulatory authorities and has been studied in randomized, double-blind, placebo-controlled clinical trials evaluating its efficacy and safety. The most commonly reported side effects are local reactions such as vaginal discharge and itching. The product is considered an investigational new drug and is currently under clinical evaluation, including Phase I and a prematurely ended Phase II study in Europe[1][2][3][6][7][8][10].

Other names

PKB171 gelPKB-171 gelPKB 171 gelpentoxifylline PKB171 gel